The Health-System Benefits and Cost-effectiveness of Using Mycobacterium Tuberculosis Direct Nucleic Acid Amplification Testing to Diagnose Tuberculosis Disease in the United States

被引:34
作者
Marks, Suzanne M. [1 ]
Cronin, Wendy [2 ]
Venkatappa, Thara [3 ]
Maltas, Gina [4 ]
Chon, Sandy [4 ]
Sharnprapai, Sharon [5 ]
Gaeddert, Mary [5 ]
Tapia, Jane [6 ]
Dorman, Susan E. [4 ]
Etkind, Sue [5 ]
Crosby, Claud [6 ]
Blumberg, Henry M. [6 ]
Bernardo, John [5 ]
机构
[1] US Ctr Dis Control & Prevent, Atlanta, GA USA
[2] Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA
[3] State Hawaii Dept Hlth, Honolulu, HI USA
[4] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[5] Massachusetts Dept Publ Hlth, Boston, MA USA
[6] Emory Univ, Sch Med, Dept Med, Div Infect Dis, Atlanta, GA USA
关键词
tuberculosis; diagnosis; molecular; cost; nucleic acid amplification;
D O I
10.1093/cid/cit336
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. The utility of Mycobacterium tuberculosis direct nucleic acid amplification testing (MTD) for pulmonary tuberculosis disease diagnosis in the United States has not been well described. Methods. We analyzed a retrospective cohort of reported patients with suspected active pulmonary tuberculosis in 2008-2010 from Georgia, Hawaii, Maryland, and Massachusetts to assess MTD use, effectiveness, health-system benefits, and cost-effectiveness. Results. Among 2140 patients in whom pulmonary tuberculosis was suspected, 799 (37%) were M. tuberculosis-culture-positive. Eighty percent (680/848) of patients having acid-fast-bacilli-smear-positive specimens had MTD performed; MTD positive-predictive value (PPV) was 98% and negative-predictive value (NPV) was 94%. Nineteen percent (240/1292) of patients having smear-negative specimens had MTD; MTD PPV was 90% and NPV was 88%. Among patients suspected of tuberculosis but not having MTD, smear PPV for lab-confirmed tuberculosis was 77% and NPV 78%. Compared with no MTD, MTD significantly decreased time to diagnosis in patients with smear-positive/MTD-positive specimens, decreased respiratory isolation for patients having smear-positive/MTD-negative/culture-negative specimens, decreased outpatient days of unnecessary tuberculosis medications, and reduced resources expended on contact investigation. While MTD generally cost more than no MTD, incremental cost savings occurred in patients with human immunodeficiency virus (HIV) or homelessness to diagnose or to exclude tuberculosis, and in patients with substance abuse having smear-negative specimens to exclude tuberculosis. Conclusions. MTD improved diagnostic accuracy and timeliness and reduced unnecessary respiratory isolation, treatment, and contact investigations. It was cost saving in patients with HIV, homelessness, or substance abuse, but not in others.
引用
收藏
页码:532 / 542
页数:11
相关论文
共 14 条
  • [1] Anonymous, 2009, Morbidity and Mortality Weekly Report, V58, P7
  • [2] [Anonymous], CONS PRIC IND MED CA
  • [3] [Anonymous], 2008, 2009 PHYS FEE COD GU
  • [4] Intensive Tuberculosis Screening for HIV-Infected Patients Starting Antiretroviral Therapy in Durban, South Africa
    Bassett, Ingrid V.
    Wang, Bingxia
    Chetty, Senica
    Giddy, Janet
    Losina, Elena
    Mazibuko, Matilda
    Bearnot, Benjamin
    Allen, Jenny
    Walensky, Rochelle P.
    Freedberg, Kenneth A.
    [J]. CLINICAL INFECTIOUS DISEASES, 2010, 51 (07) : 823 - 829
  • [5] Branson Bernard M., 2006, Morbidity and Mortality Weekly Report, V55, P1
  • [6] Bureau of Labor Statistics, AV HOURL EARN PROD N
  • [7] Cost-effectiveness analysis of the gen-probe amplified mycobacterium tuberculosis direct test as used routinely on smear-positive respiratory specimens
    Dowdy, DW
    Maters, A
    Parrish, N
    Beyrer, C
    Dorman, SE
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (03) : 948 - 953
  • [8] Diagnostic standards and classification of tuberculosis in adults and children
    Dunlap, NE
    Bass, J
    Fujiwara, P
    Hopewell, P
    Horsburgh, CR
    Salfinger, M
    Simone, PM
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 161 (04) : 1376 - 1395
  • [9] Current evidence on diagnostic accuracy of commercially based nucleic acid amplification tests for the diagnosis of pulmonary tuberculosis
    Greco, S.
    Girardi, E.
    Navarra, A.
    Saltini, C.
    [J]. THORAX, 2006, 61 (09) : 783 - 790
  • [10] Use of the amplified Mycobacterium tuberculosis direct test in a public health laboratory -: Test performance and impact on clinical care
    Guerra, Renata L.
    Hooper, Nancy M.
    Baker, James F.
    Alborz, Roya
    Armstrong, Derek T.
    Maltas, Gina
    Kiehlbauch, Julia A.
    Dorman, Susan E.
    [J]. CHEST, 2007, 132 (03) : 946 - 951